Drugs -- Testing
Resource Information
The concept Drugs -- Testing represents the subject, aboutness, idea or notion of resources found in Indiana State Library.
The Resource
Drugs -- Testing
Resource Information
The concept Drugs -- Testing represents the subject, aboutness, idea or notion of resources found in Indiana State Library.
- Label
- Drugs -- Testing
- Authority link
- (EG-IN)1313008
78 Items that share the Concept Drugs -- Testing
Context
Context of Drugs -- TestingSubject of
No resources found
No enriched resources found
- Why volunteer? : clinical trials of medical treatments
- Addendum to ICH S6 : preclinical safety evaluation of biotechnology-derived pharmaceuticals
- Answers to questions on selected FDA Bureau of Biologics' regulation activities : report
- Appendix : the request of the National Institutes of Health for a limited exemption from the Freedom of Information Act
- Budget amendment for program of monitoring the testing of drugs and food additives : communication from the President of the United States ... April 26, 1976
- CDC trials of daily oral tenofovir for preventing HIV infection : phase II and III clinical trials in Botswana, Thailand and the United States
- Competitive problems in the drug industry : drug testing : summary and analysis
- Drug bioequivalence
- El proceso del desarrollo de las drogas y la FDA : cómo la agencia asegura que las drogas sean seguras y efectivas
- Ensayos voluntarios de tratamientos médicos en clínicas experimentales
- FDA and the drug development process : how the agency ensures that drugs are safe and effective
- FDA drug approval : a lengthy process that delays the availability of important new drugs : summary : report to the Subcommittee on Science, Research, and Technology, House Committee on Science and Technology
- FDA-approved bargain drugs : generic products must meet high standards
- Food and Drug Administration : FDA faces challenges meeting its growing medical product responsibilities and should develop complete estimates of its resource needs : report to congressional requesters
- General considerations for the clinical evaluation of drugs
- General considerations for the clinical evaluation of drugs in infants and children
- Guidance for industry : CGMP for phase 1 investigational drugs
- Guidance for industry : E 11 clinical investigation of medicinal products in the pediatric population
- Guidance for industry : E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs
- Guidance for industry : E2B(M), data elements for transmission of individual case study reports, questions and answers
- Guidance for industry : E2BM data elements for transmission of individual case safety reports
- Guidance for industry : M3 nonclinical safety studies for the conduct of human clinical trials for pharmaceuticals
- Guidance for industry : Q1A(R2) stability testing of new drug substances and products
- Guidance for industry : Q1D bracketing and matrixing designs for stability testing of new drug substances and products
- Guidance for industry : Q3C impurities, residual solvents
- Guidance for industry : S1B testing for carcinogenicity of pharmaceuticals
- Guidance for industry : S6 preclinical safety evaluation of biotechnology-derived pharmaceuticals
- Guidance for industry : S7B nonclinical evaluation of the potential for delayed ventricular repolarization (QT Interval Prolongation) by human pharmaceuticals
- Guidance for industry : S8 immunotoxicity studies for human pharmaceuticals
- Guidance for industry : addendum to E2C clinical safety data management : periodic safety update reports for marketed drugs
- Guidance for industry : drug-induced liver injury, premarketing clinical evaluation
- Guidance for industry : estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers
- Guidance for industry : process validation, general principles and practices
- Guidance for industry : tropical disease priority review vouchers
- Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals
- Guideline for the format and content of the clinical and statistical sections of an application
- Guidelines for the clinical evaluation of G.I. motility-modifying drugs
- Guidelines for the clinical evaluation of antacid drugs
- Guidelines for the clinical evaluation of anti-anginal drugs
- Guidelines for the clinical evaluation of anti-arrhythmic drugs
- Guidelines for the clinical evaluation of anti-infective drugs (systemic) : adults and children
- Guidelines for the clinical evaluation of anti-inflammatory drugs (adults and children)
- Guidelines for the clinical evaluation of antianxiety drugs
- Guidelines for the clinical evaluation of anticonvulsant drugs (adults and children)
- Guidelines for the clinical evaluation of antidepressant drugs
- Guidelines for the clinical evaluation of antidiarrheal drugs
- Guidelines for the clinical evaluation of antiepileptic drugs (adults and children)
- Guidelines for the clinical evaluation of antineoplastic drugs
- Guidelines for the clinical evaluation of bronchodilator drugs
- Guidelines for the clinical evaluation of drugs to prevent dental caries
- Guidelines for the clinical evaluation of drugs to prevent, control and/or treat periodontal disease
- Guidelines for the clinical evaluation of drugs used in the treatment of osteoporosis
- Guidelines for the clinical evaluation of gastric secretory depressant (GSD) drugs
- Guidelines for the clinical evaluation of general anesthetics
- Guidelines for the clinical evaluation of hypnotic drugs
- Guidelines for the clinical evaluation of laxative drugs
- Guidelines for the clinical evaluation of lipid-altering agents in adults and children
- Guidelines for the clinical evaluation of local anesthetics
- Guidelines for the clinical evaluation of radiopharmaceutical drugs
- Improving public health : promting safe and effective drug use
- Investigator's handbook : a manual for participants in clinical trails of investigational agents sponsored by the Division of Cancer Treatment, National Cancer Institute
- Las drogas baratas aprobadas por la FDA : los productos genéricos deben satisfacer altos niveles
- Manual del Centro para la Evaluacion e Investigacion de Farmacos
- Mejorando la salud pública : fomentando la venta y el uso de drogas efectivas
- Pediatric drug research : Food and Drug Administration should more efficiently monitor inclusion of minority children
- Pharmacokinetics : guidance for repeated dose tissue distribution studies
- Postmarketing surveillance of prescription drugs
- Preclinical and clinical testing by the pharmaceutical industry, 1976 : joint hearings before the Subcommittee on Health of the Committee on Labor and Public Welfare and the Subcommittee on Administrative Practice and Procedure of the Committee on the Judiciary, United States Senate, Ninety-fourth Congress, second session, on examination of the process of drug testing and FDA's role in the regulation and conditions under which such testing is carried out ..
- Preclinical and clinical testing by the pharmaceutical industry, 1979 : hearing before the Subcommittee on Health and Scientific Research of the Committee on Labor and Human Resources, United States Senate, Ninety-sixth Congress, first session ... October 11, 1979
- Prescription drugs : FDA guidance and regulations related to data on elderly persons in clinical drug trials
- Revision of the ICH guideline on clinical safety data management : data elements for transmission of individual case safety reports
- S2(R1) genotoxicity testing and data interpretation for pharmaceuticals intended for human use
- Speeding up the drug review process, results encouraging, but progress slow : report
- Summary of the report of the Advisory Review Panel
- The life/death ratio : benefits and risks in modern medicines
- The request of the National Institutes of Health for a limited exemption from the Freedom of Information Act
- Visita radial a ClinicalTrials.gov : preguntas y respuestas
- What you should know about the basal cell carcinoma prevention trial
Embed
Settings
Select options that apply then copy and paste the RDF/HTML data fragment to include in your application
Embed this data in a secure (HTTPS) page:
Layout options:
Include data citation:
<div class="citation" vocab="http://schema.org/"><i class="fa fa-external-link-square fa-fw"></i> Data from <span resource="http://link.library.in.gov/resource/4OZqTQuscps/" typeof="CategoryCode http://bibfra.me/vocab/lite/Concept"><span property="name http://bibfra.me/vocab/lite/label"><a href="http://link.library.in.gov/resource/4OZqTQuscps/">Drugs -- Testing</a></span> - <span property="potentialAction" typeOf="OrganizeAction"><span property="agent" typeof="LibrarySystem http://library.link/vocab/LibrarySystem" resource="http://link.library.in.gov/"><span property="name http://bibfra.me/vocab/lite/label"><a property="url" href="http://link.library.in.gov/">Indiana State Library</a></span></span></span></span></div>
Note: Adjust the width and height settings defined in the RDF/HTML code fragment to best match your requirements
Preview
Cite Data - Experimental
Data Citation of the Concept Drugs -- Testing
Copy and paste the following RDF/HTML data fragment to cite this resource
<div class="citation" vocab="http://schema.org/"><i class="fa fa-external-link-square fa-fw"></i> Data from <span resource="http://link.library.in.gov/resource/4OZqTQuscps/" typeof="CategoryCode http://bibfra.me/vocab/lite/Concept"><span property="name http://bibfra.me/vocab/lite/label"><a href="http://link.library.in.gov/resource/4OZqTQuscps/">Drugs -- Testing</a></span> - <span property="potentialAction" typeOf="OrganizeAction"><span property="agent" typeof="LibrarySystem http://library.link/vocab/LibrarySystem" resource="http://link.library.in.gov/"><span property="name http://bibfra.me/vocab/lite/label"><a property="url" href="http://link.library.in.gov/">Indiana State Library</a></span></span></span></span></div>
